Preclinical characterization of a novel class of 18F-labeled PET tracers for amyloid-β

Journal of Nuclear Medicine

Volumn 53, Issue 11, 2012, Pages 1794-1801

  Brockschnieder, Damian ^a   Schmitt Willich, Heribert ^a   Heinrich, Tobias ^a   Varrone, Andrea ^b   Gulyás, Balázs ^b   Toth, Miklos ^b   Andersson, Jan ^b   Boemer, Ulf ^a   Krause, Sabine ^a   Friebe, Matthias ^c   Dinkelborg, Ludger ^c   Halldin, Christer ^b   Dyrks, Thomas ^a  

^a BAYER PHARMA AG   (Germany)

^b KAROLINSKA INSTITUTE   (Sweden)

^c Piramal Enterprises Limited   (India)

Author keywords

Alzheimer's disease; Amyloid beta; Dementia diagnosis; PET imaging

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; BAY 1008472; FLORBETABEN; TRACER; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN HOMOGENATE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG PENETRATION; DRUG RETENTION; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG UPTAKE; EX VIVO STUDY; FEMALE; FRONTOTEMPORAL DEMENTIA; GRAY MATTER; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MALE; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOACTIVITY; RHESUS MONKEY; WHITE MATTER;

AMYLOID BETA-PEPTIDES; ANIMALS; FEMALE; FLUORINE RADIOISOTOPES; FRONTAL LOBE; HALF-LIFE; HUMANS; MACACA MULATTA; MALE; MICE; POSITRON-EMISSION TOMOGRAPHY; PYRIDINES; RADIOACTIVE TRACERS;

EID: 84868317595     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.104810     Document Type: Article

References (38)

1. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297:353-356.
2. Gelosa G, Brooks DJ. The prognostic value of amyloid imaging. Eur J Nucl Med Mol Imaging. 2012;39:1207-1219.
3. Reinke AA, Gestwicki JE. Insight into amyloid structure using chemical probes. Chem Biol Drug Des. 2011;77:399-411.
4. Mirra SS, Heyman A, McKeel D, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II: standardization of the neuropathologic assessment of Alzheimer's disease. Neurology. 1991;41:479-486.
5. Hyman BT, Trojanowski JQ. Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan InstituteWorking Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease. J Neuropathol Exp Neurol. 1997;56:1095-1097.
6. Fagan AM, Mintun MA, Mach RH, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol. 2006;59:512-519.
7. Trojanowski JQ, Vandeerstichele H, Korecka M, et al. Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects. Alzheimers Dement. 2010;6:230-238.
8. De Meyer G, Shapiro F, Vanderstichele H, et al. Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch Neurol. 2010;67:949-956.
9. 18F-florbetaben in Alzheimer disease and other dementias. J Nucl Med. 2011;52:1210-1217.
10. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306-319.
11. 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol. 2008;7:129-135.
12. 18F-AV-45 (florbetapir [corrected] F 18). J Nucl Med. 2010;51:913-920.
13. 18F- flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol. 2010;68:319-329.
14. 18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol. 2011;10:424-435.
15. Dubois B, Feldman HH, Jacova C, et al. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol. 2010;9:1118-1127.
16. Jack CR Jr, Albert MS, Knopman DS, et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:257-262.
17. Ono M. Development of positron-emission tomography/single-photon emission computed tomography imaging probes for in vivo detection of beta-amyloid plaques in Alzheimer's brains. Chem Pharm Bull (Tokyo). 2009;57:1029-1039.
18. Juréus A, Swahn BM, Sandell J, et al. Characterization of AZD4694, a novel fluorinated Abeta plaque neuroimaging PET radioligand. J Neurochem. 2010; 114:784-794.
19. 18F stilbenes and styrylpyridines for PET imaging of A beta plaques in Alzheimer's disease: a miniperspective. J Med Chem. 2010;53:933-941.
20. Klunk WE, Debnath ML, Pettegrew JW. Development of small molecule probes for the beta-amyloid protein of Alzheimer's disease. Neurobiol Aging. 1994;15: 691-698.
21. Schmitt-Willich H, Roehn U, Friebe M, et al. Preparation of isotopelabeled piperazine derivatives for binding and imaging amyloid plaques and their use. PCT International Application WO 2010028776 A1 20100318. 2010.
22. 3H] vardenafil, Levitra, using a new labeling technique. J Labelled Comp Radiopharm. 2003;46:1241-1247.
23. 18F-labeled piperazine derivative as PET imaging agent of amyloid plaques. PCT International Application WO 2011095593. 2011.
24. 18F]-florbetaben, an Abeta imaging radiotracer. Nucl Med Biol. April 11, 2012 [Epub ahead of print].
25. Hsiao K, Chapman P, Nilsen S, et al. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science. 1996;274:99-102.
26. Guidelines for Planning, Conducting and Documenting Experimental Research. Available from: http://ki.se/content/1/c6/09/78/88/experimentell-en. pdf. Accessed August 24, 2012.
27. Guide for the Care and Use of Laboratory Animals. Bethesda, MD: National Institutes of Health; 1985. NIH publication 85-23.
28. 18F]FMeNER-D (2). Eur J Nucl Med Mol Imaging. 2009;36:1308-1314.
29. Varrone A, Sjoholm N, Eriksson L, Gulyas B, Halldin C, Farde L. Advancement in PET quantification using 3D-OP-OSEM point spread function reconstruction with the HRRT. Eur J Nucl Med Mol Imaging. 2009;36:1639-1650.
30. Halldin C, Gulyas B, Langer O, Farde L. Brain radioligands: state of the art and new trends. Q J Nucl Med. 2001;45:139-152.
31. Laruelle M, Slifstein M, Huang Y. Relationships between radiotracer properties and image quality in molecular imaging of the brain with positron emission tomography. Mol Imaging Biol. 2003;5:363-375.
32. Zhang W, Oya S, Kung MP, Hou C, Maier DL, Kung HF. F-18 stilbenes as PET imaging agents for detecting beta-amyloid plaques in the brain. J Med Chem. 2005;48:5980-5988.
33. 18F-AV-45: a PETagent for Abeta plaques in the brain. J Nucl Med. 2009;50:1887-1894.
34. LeVine H 3rd. Multiple ligand binding sites on A beta(1-40) fibrils. Amyloid. 2005;12:5-14.
35. Vernon AC, Ballard C, Modo M. Neuroimaging for Lewy body disease: is the in vivo molecular imaging of alpha-synuclein neuropathology required and feasible? Brain Res Rev. 2010;65:28-55.
36. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol. 2010;9:363-372.
37. Berti V, Pupi A, Mosconi L. PET/CT in diagnosis of dementia. Ann N Y Acad Sci. 2011;1228:81-92.
38. Jellinger KA. Basic mechanisms of neurodegeneration: a critical update. J Cell Mol Med. 2010;14:457-487.